Ye Liu
State Key Laboratory Of Female Fertility Promotion, NHC Key Laboratory Of Cardiovascular Molecular Biology And Regulatory Peptides
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Effects of time-restricted eating on glycemic control in type 2 diabetes: A 12-week quasi-experimental single-arm study with 1-year follow-up.
Journal: Clinical nutrition (Edinburgh, Scotland)
Published: November 11, 2024
Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review.
Journal: Diabetes, obesity & metabolism
Published: December 13, 2022
No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.
Journal: Diabetes/metabolism research and reviews
Published: November 20, 2017
Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Journal: Diabetes, obesity & metabolism
Published: September 04, 2017
The pathogenesis and management of non-alcoholic fatty liver disease coexisted with type 2 diabetes
Journal: Zhonghua yi xue za zhi
Published: January 28, 2016
Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner.
Journal: American journal of physiology. Endocrinology and metabolism
Published: September 04, 2015
Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
Journal: American journal of physiology. Endocrinology and metabolism
Published: May 08, 2014
Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.
Journal: World journal of gastroenterology
Published: December 30, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026